Mogelijk gemaakt door Google TranslateTranslate
Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Latest Press Releases
View all
TimeHeadline
9h agoDelivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
10h agoRefers to Item 7 on the agenda: Report on the audit of the consolidated financial statements of Grupa Kęty SA
12h agoThe 4th BOCHK Science and Technology Innovation Prize Award Ceremony Concludes with Great Success
19h agoBuffalo Potash Files Annual Information Form and New Technical Report
20h agoIonik Announces 30-Day Extension of Senior Debt Facility
Merck Kgaa logo

Merck Kgaa

About

128.60EUR+2.20 +1.74%
Closed • Updated at 23:17 GMT+00:00
Market Cap$64.95B
P/E Ratio22.08
Volume371.8K
Beta1.48
RSI70.98
Gross Margin58.53%
Health TechnologyPharmaceuticals: Major

Merck Kgaa — investor relations, events, news, and company updates on 6ix.

Latest News

May 21 2026
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
May 7 2026
MilliporeSigma Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies
Apr 30 2026
Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
Apr 28 2026
Remepy Announces Collaboration with Merck KGaA, Darmstadt Germany to Advance Hybrid Drugs Across Therapeutic Areas
Apr 21 2026
MilliporeSigma Launches First Bio-Based Solvent Portfolio for High-Performance Liquid Chromatography

Community Chat

Ask AI

Try asking
6ix6ixAIEvents